Leqvio (Inclisiran): A Cardiologist's Guide to the Twice-Yearly Cholesterol Injection

Leqvio (inclisiran) is the first FDA-approved small interfering RNA (siRNA) therapy in cardiology. It silences PCSK9 production in the liver, allowing LDL receptors to clear more LDL cholesterol from the blood. Two subcutaneous injections per year produce a sustained 45 to 50% LDL reduction. In my Encinitas practice, inclisiran has become an important option for patients who need additional LDL lowering beyond statin plus ezetimibe, who cannot tolerate statins, or who struggle with daily medication adherence. This guide walks through the mechanism, the trial evidence, who benefits, and how to use it.

What Is Leqvio (Inclisiran)?

Leqvio (inclisiran) is a small interfering RNA (siRNA) drug that targets and degrades PCSK9 messenger RNA in the liver. With less PCSK9 produced, more LDL receptors are recycled to the hepatocyte surface, where they clear LDL particles from the bloodstream. The result is a sustained 45 to 50% LDL reduction with twice-yearly dosing.

Inclisiran is a synthetic, chemically stabilized, double-stranded RNA molecule conjugated to a GalNAc (N-acetylgalactosamine) ligand. The GalNAc ligand binds to the asialoglycoprotein receptor on hepatocytes, delivering the siRNA selectively to the liver. Once inside, the siRNA loads onto the RISC complex and degrades the messenger RNA that codes for PCSK9. With less PCSK9 protein produced, fewer LDL receptors are tagged for destruction, and more receptors are available to clear LDL particles. The mechanism is upstream of the protein-level inhibition produced by monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab).

PCSK9 itself is a protein the liver produces that binds LDL receptors and marks them for lysosomal degradation. The natural function is to fine-tune the LDL clearance rate. Loss-of-function PCSK9 variants are associated with lifelong low LDL (30 to 50 mg/dL) and dramatically reduced cardiovascular risk, with no apparent harm. Gain-of-function variants cause severe familial hypercholesterolemia. Both observations made PCSK9 a high-value drug target.

The result of silencing PCSK9 in a treated patient is a roughly 45 to 50% reduction in LDL, on top of whatever the patient is already taking. The effect appears within weeks of the first dose and is sustained at 6 months between doses, which is the basis for the twice-yearly schedule.

How Is Leqvio Dosed and Administered?

Inclisiran is given as a subcutaneous injection of 284 mg at day 0, day 90, and then every 6 months thereafter. No weight or kidney-based dose adjustment. The injection is administered at an infusion center, the medical office, or, increasingly, at home by a trained patient or caregiver.

The standardized dose of 284 mg is the same for every patient regardless of weight, baseline LDL, kidney function, or liver function. The first two doses are 90 days apart to establish steady-state PCSK9 silencing, then the maintenance interval is 6 months. The injection volume is small (1.5 mL), the needle is fine, and the procedure takes seconds. Most patients report no discomfort or only mild transient stinging.

The medication arrives at the administering site as a prefilled syringe, clear and colorless. Storage is refrigerated. There is no fasting required, no monitoring during administration, and no post-injection observation. Patients drive home and resume normal activity immediately.

Insurance authorization is the most common practical barrier. Most commercial insurance and Medicare Part D plans cover inclisiran for appropriate indications (ASCVD or HeFH with LDL above goal on a maximally tolerated statin), but prior authorization is typically required, and the documentation is meaningful. Manufacturer assistance programs and copay support exist for eligible patients.

What Is the Clinical Trial Evidence for Inclisiran?

The Phase 3 ORION-9, ORION-10, and ORION-11 trials established that inclisiran reduces LDL by 45 to 50% on top of a maximally tolerated statin, sustained over 18 months of follow-up. The cardiovascular outcomes trial ORION-4 (~15,000 patients with established ASCVD) is ongoing, with results expected in 2026 to 2027.

Inclisiran Trial Evidence at a Glance

The ORION-10 and ORION-11 trials (Ray et al., NEJM 2020) randomized roughly 1,500 patients each to inclisiran or placebo. After 18 months, mean LDL reduction was 52% in ORION-10 and 50% in ORION-11 compared to placebo. The effect was consistent across baseline LDL ranges, age groups, statin intensities, and presence or absence of ezetimibe. Inclisiran did not require dose titration; the standardized 284 mg subcutaneous regimen worked across the population.

The cardiovascular outcomes question is the most important still-open one. ORION-4 enrolled approximately 15,000 patients with established ASCVD and is following them for an average of 5 years with a primary endpoint of major adverse cardiovascular events. The trial is expected to read out in 2026 to 2027. If the cardiovascular benefit tracks the LDL reduction (which the IMPROVE-IT, FOURIER, and ODYSSEY OUTCOMES trials all suggest it should), inclisiran will be confirmed as a class-equivalent alternative to PCSK9 monoclonal antibodies with a major dosing-frequency advantage.

VICTORION-INCEPTION, a complementary trial in post-acute-coronary-syndrome patients, is testing aggressive early inclisiran initiation and reading out on a similar timeline.

Who Is a Candidate for Leqvio?

The clearest candidates are adults with established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia whose LDL is above goal on a maximally tolerated statin plus ezetimibe. Inclisiran is also useful for statin-intolerant patients and patients whose adherence to daily medication is unreliable.

I think about candidacy in tiers.

Tier 1, patients with established ASCVD on a maximally tolerated statin plus ezetimibe whose LDL remains above 70 mg/dL (or above 55 mg/dL in very high-risk patients with recurrent events, diabetes plus ASCVD, or elevated Lp(a)). These patients are the strongest candidates and have the clearest indication.

Tier 2, patients with heterozygous familial hypercholesterolemia whose LDL remains above goal on maximal lipid-lowering therapy. Inclisiran has a specific FDA indication for HeFH.

Tier 3, patients with documented statin intolerance who have failed multiple statins and dose-reduction strategies. The 2026 ACC/AHA dyslipidemia guideline framework allows non-statin LDL-lowering therapy in confirmed intolerance. Inclisiran is a clean fit because it does not have the muscle-symptom association that drives most statin discontinuations.

Tier 4, patients whose daily medication adherence is unreliable due to cognitive impairment, complex polypharmacy, work or travel schedules, or other practical barriers. Two injections per year, given in clinic, removes the daily-adherence challenge entirely. This is one of the most underappreciated practical advantages of inclisiran in real-world practice.

Inclisiran is generally not a substitute for a statin in patients who tolerate one. The pleiotropic effects of statin therapy (anti-inflammatory, plaque-stabilizing) are real and additive to LDL reduction. The right framing for most patients is “statin + ezetimibe + inclisiran when needed,” not “inclisiran instead of statin.”

Contraindications and cautions: pregnancy and breastfeeding (safety not established), severe hepatic impairment (limited data), and known hypersensitivity to the components.

How Does Leqvio Compare to PCSK9 Monoclonal Antibody Inhibitors?

Both classes silence PCSK9 and produce similar magnitudes of LDL reduction (~50%). The differences are dosing frequency (inclisiran twice a year vs PCSK9 antibodies every 2 to 4 weeks), mechanism (siRNA degrading PCSK9 mRNA vs monoclonal antibody binding PCSK9 protein), and the available outcomes evidence (PCSK9 antibodies have completed cardiovascular outcomes trials; inclisiran’s outcomes data is pending).

Inclisiran vs PCSK9 Monoclonal Antibodies

The choice between inclisiran and a monoclonal antibody is partly practical (injection frequency tolerance, insurance coverage, patient preference) and partly evidence-based (the monoclonal antibodies have completed cardiovascular outcomes trials; inclisiran’s ORION-4 is expected in 2026 to 2027). For an adherence-challenged patient, inclisiran’s twice-yearly schedule is decisive. For a patient who self-injects without difficulty and wants the deepest outcomes evidence, evolocumab or alirocumab may be preferred. Both classes can be combined with statin and ezetimibe; they are not combined with each other.

What Are the Side Effects of Leqvio?

The most common side effect is a mild injection-site reaction (redness, swelling, or tenderness) in about 5% of patients, usually resolving within a few days. Beyond that, inclisiran has an excellent safety profile with no clinically significant systemic side effects, no muscle symptoms, no liver enzyme elevations, no neurocognitive concerns, and no significant drug interactions.

Injection-site reactions are the dominant tolerability finding in the ORION trials. They are mild, self-limited, and rarely a reason to discontinue. Modifying injection technique (allowing the syringe to warm to room temperature, varying the site between upper arm, abdomen, and thigh) reduces the rate further.

Beyond the injection site, the systemic safety profile is excellent. Inclisiran does not affect muscle (no statin-myalgia-like syndrome), does not affect liver enzymes meaningfully, does not affect cognition, and has not been associated with clinically significant immunogenicity. The pooled ORION trials and post-marketing surveillance have not identified an emerging safety signal at the population level.

Drug-drug interactions are minimal. Inclisiran does not affect CYP enzyme activity meaningfully and is not metabolized through pathways that interact with common cardiovascular drugs. It can be combined freely with statins, ezetimibe, bempedoic acid, DOACs, ARBs, beta-blockers, and SGLT2 inhibitors.

Allergic reactions are rare but possible, as with any injectable. The expected presentation would be local hives or, very rarely, more systemic features within minutes of injection. The medical team administering the injection is equipped to recognize and treat anaphylaxis if it occurs.

Long-term safety data is now extending through several years of registry follow-up. So far, no concerning signals have emerged.

What Should You Expect on Leqvio Treatment?

Expect a 45 to 50% additional LDL reduction within 30 to 60 days of the first injection, sustained throughout the 6-month interval between doses. LDL is typically checked at 3 to 6 months and then every 6 months thereafter. No dose adjustment based on LDL response. Most patients require continued statin (plus ezetimibe) in combination with inclisiran to reach goal.

The LDL trajectory after the first injection looks like this: LDL starts to fall within about 2 weeks, reaches near-nadir by day 30 to 60, and stays at the new level through day 90. The day 90 dose maintains the suppression. Every 6 months thereafter, the dose resets the cycle.

I check the lipid panel 4 to 6 weeks after the first injection to confirm response, and then every 6 months alongside the maintenance injection schedule. Routine PCSK9 levels are not necessary. Liver function tests are not required (LDL reduction is the relevant readout).

Most patients on inclisiran also continue a statin and ezetimibe. The reason is layering: each agent contributes additively to LDL reduction, and the goal in high-risk patients is to drive LDL into the < 55 mg/dL or even < 40 mg/dL range. Stopping the statin to “simplify” therapy almost always undoes most of the benefit, the statin’s anti-inflammatory and plaque-stabilizing effects are valuable independent of LDL reduction.

How Should You Decide About Leqvio?

Consider Leqvio if you have ASCVD or HeFH and your LDL is above goal on a maximally tolerated statin plus ezetimibe; if you cannot tolerate statins; or if your daily medication adherence is unreliable. The decision should be made with a cardiologist or lipid specialist who can assess your risk profile, current therapy, insurance coverage, and personal preference about injection frequency.

The decision is rarely close in the right patient. An ASCVD patient on atorvastatin 80 mg plus ezetimibe with an LDL of 95 mg/dL is exactly the candidate the trials enrolled, and the choice is typically between inclisiran twice-yearly, a PCSK9 monoclonal antibody every 2 to 4 weeks, or continued LDL above goal. The “above goal” option is the wrong answer. The other two are both correct, with selection driven by injection-frequency preference, insurance coverage, and the available outcomes evidence at the time of decision.

In my Encinitas practice, the most common scenario is a post-MI patient still above LDL goal at 6 to 12 months despite maximum statin and ezetimibe. The choice between inclisiran and a monoclonal antibody is part of the visit conversation, and the right answer differs by patient.

Cost considerations are real. Both classes are specialty drugs with significant list prices, though insurance coverage and manufacturer assistance programs reduce out-of-pocket costs substantially for most patients with appropriate indications.

Frequently Asked Questions About Leqvio (Inclisiran)

How often is Leqvio given?

Two injections in the first year (day 0 and day 90), then twice a year thereafter. Standard dose is 284 mg subcutaneously.

How much does Leqvio lower LDL cholesterol?

About 45 to 50% additional LDL reduction on top of a maximally tolerated statin, sustained over the 6-month interval between doses. The effect is dose-independent at the FDA-approved dose, the standardized 284 mg works across the population.

Is Leqvio safer than a statin?

Inclisiran has a different side-effect profile than statins. There is no muscle-symptom signal, no liver enzyme issue, and no cognitive effect. The most common side effect is a mild local injection-site reaction. For statin-intolerant patients, this is a meaningful advantage. For patients who tolerate statins, the two are complementary, not alternatives, because statins have pleiotropic effects beyond LDL reduction.

Does Leqvio replace my statin?

Usually no. Most patients on inclisiran continue a statin (plus ezetimibe) because the combination produces deeper LDL reduction than any single agent and because statins have additional anti-inflammatory and plaque-stabilizing benefits. Inclisiran replaces the daily PCSK9 monoclonal antibody option for many patients but does not replace the statin in most.

How long until Leqvio works?

LDL starts to drop within 2 weeks of the first injection and reaches near-nadir by day 30 to 60. I check the lipid panel at 4 to 6 weeks.

Can I take Leqvio if I have kidney disease?

Yes. No dose adjustment is required for any degree of kidney impairment, including patients on dialysis. This is a meaningful advantage over some other lipid-lowering agents.

Are there any drug interactions?

Minimal. Inclisiran can be combined freely with statins, ezetimibe, bempedoic acid, DOACs (apixaban, rivaroxaban), ARBs, beta-blockers, SGLT2 inhibitors, and GLP-1 receptor agonists. It does not affect CYP enzyme activity meaningfully.

Is Leqvio covered by insurance?

Most commercial insurance and Medicare Part D cover inclisiran for appropriate indications (ASCVD or HeFH with LDL above goal on maximum statin). Prior authorization is typically required. Manufacturer assistance programs and copay support exist for eligible patients.

References

1. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). New England Journal of Medicine. 2020;382(16):1507-1519.

2. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (ORION-9). New England Journal of Medicine. 2020;382(16):1520-1530.

3. Wright RS, Ray KK, Raal FJ, et al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 2021;77(9):1182-1193.

4. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-Term Efficacy and Safety of Inclisiran in Patients with High Cardiovascular Risk and Elevated LDL Cholesterol (ORION-3). Lancet Diabetes & Endocrinology. 2023;11(2):109-119.

5. ORION-4 Trial: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Cardiovascular Disease. ClinicalTrials.gov NCT03705234. Ongoing.

6. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). New England Journal of Medicine. 2017;376(18):1713-1722.

7. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). New England Journal of Medicine. 2018;379(22):2097-2107.

8. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-e350.

9. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026.

10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41(1):111-188.